...
首页> 外文期刊>Endocrine Connections >Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
【24h】

Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy

机译:醋酸环丙孕酮或螺内酯可降低接受雌二醇治疗的变性人的睾丸激素浓度

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy; however, there is no evidence to guide optimal treatment choice. Objective We aimed to compare add-on cyproterone acetate versus spironolactone in lowering endogenous testosterone concentrations in transfeminine individuals. Design Retrospective cross-sectional study. Methods We analysed 114 transfeminine individuals who had been on oestradiol therapy for &6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; oestradiol alone ( n ?=?21), oestradiol plus cyproterone acetate ( n ?=?21) and oestradiol plus spironolactone ( n ?=?38). Secondary outcomes included serum oestradiol concentration, oestradiol valerate dose, blood pressure, serum potassium, urea and creatinine. Results Median age was 27.0 years (22.5–45.1) and median duration of hormone therapy was 1.5 years (0.9–2.6), which was not different between groups. On univariate analysis, the cyproterone group had significantly lower total testosterone concentrations (0.8?nmol/L (0.6–1.20)) compared with the spironolactone group (2.0?nmol/L (0.9–9.4), P ?=?0.037) and oestradiol alone group (10.5?nmol/L (4.9–17.2), P ?&?0.001), which remained significant ( P ?=?0.005) after adjustments for oestradiol concentration, dose and age. Serum urea was higher in the spironolactone group compared with the cyproterone group. No differences were observed in total daily oestradiol dose, blood pressure, serum oestradiol, potassium or creatinine. Conclusions The cyproterone group achieved serum total testosterone concentrations in the female reference range. As spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Further prospective studies are required.
机译:背景技术在没有进行过睾丸切除术的跨女性患者中,通常开有或不带有抗雄激素的雌二醇(醋酸环丙孕酮或螺内酯)。但是,没有证据可以指导最佳治疗选择。目的我们旨在比较醋酸环丙孕酮和螺内酯在降低女性女性内源性睾丸激素浓度中的作用。设计回顾性横断面研究。方法我们分析了在澳大利亚墨尔本的两家性别诊所接受过雌二醇治疗≥6个月的114例女性女性。比较三组之间的总睾丸激素浓度;单独的雌二醇(η=?21),雌二醇加醋酸环丙孕酮(η=?21)和雌二醇加螺内酯(η=?38)。次要结果包括血清雌二醇浓度,戊酸雌二醇剂量,血压,血清钾,尿素和肌酐。结果中位年龄为27.0岁(22.5–45.1),中位激素治疗时间为1.5年(0.9–2.6),两组之间无差异。单因素分析显示,与螺内酯组(2.0?nmol / L(0.9-9.4),P == 0.037)和雌二醇相比,环丙孕酮组的总睾丸激素浓度(0.8?nmol / L(0.6-1.20))要低得多。单独组(10.5nmol / L(4.9-17.2),P <0.001),在调整雌二醇浓度,剂量和年龄后仍保持显着水平(P = 0.005)。螺内酯组的血清尿素水平高于环丙孕酮组。在每日总雌二醇剂量,血压,血清雌二醇,钾或肌酐中未观察到差异。结论环丙孕酮组的女性血清总睾丸激素浓度在女性参考范围内。由于螺内酯可能会导致女性化而不会抑制类固醇生成,因此尚不清楚哪种抗雄激素在女性化方面更有效。需要进一步的前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号